For most people, common viruses aren’t major health challenges. However, for immunocompromised individuals, certain viruses can pose major threats to their health. Our current focus at Chimerix is on discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients.
Our lead product candidate, brincidofovir, is a clinical-stage nucleotide analog that has shown broad spectrum in vitro antiviral activity against the most important DNA viruses that affect humans, including adenovirus, the virus that causes smallpox (Variola) and cytomegalovirus (CMV). Brincidofovir tablets, oral suspension and intravenous formulations are in development.
Chimerix completed the AdVise trial of brincidofovir for the treatment of adenovirus infection in allogeneic stem cell transplant recipients. View the final data here. The company has initiated the AdAPT (Adenovirus After Pediatric Transplantation) study, a comparative trial of brincidofovir for the treatment of adenovirus in pediatric stem cell transplant recipients. For more information on the AdAPT trial, visit clinicaltrials.gov.
Significant morbidity (disease state) and mortality are associated with CMV and other viral infections in the first-year post transplant. A mortality rate of approximately 1 in 5 patients during the first year following stem cell transplant is independent of mortality from relapse of the underlying disease. This 20 percent increase in the hazard for non-relapse mortality is caused by post-transplant complications—including viral infections like CMV in particular—as well as other viral, bacterial and fungal infections, and graft failure.
There are no approved therapies for the prevention of BK virus in kidney transplant or stem cell transplant recipients. Available antivirals are associated with known toxicities, such as bone marrow suppression and renal impairment. The prevalence of BK virus in adults is 65 to 90 percent,18 and detection of BK virus in the urine occurs in 30 to 40 percent of patients after kidney transplant, and in 20 to 80 percent of patients after stem cell transplant.19,20 In patients who have received a stem cell transplant, BK virus can cause significant infections of the bladder and kidney.
In 2011, Chimerix received a grant of $81 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to continue exploring the development of brincidofovir (CMX001) as a medical countermeasure to treat potential smallpox outbreaks in the event of a bioterror attack or accidental release. If successful, brincidofovir could be an important contribution to the U.S. national security and public health preparedness for the treatment of smallpox—a virus for which there is no approved treatment. Read More »